Predictors of hepatotoxicity in patients receiving CDK4/6 inhibitors: A real-world cohort study [0.03%]
cyclin依赖性激酶4和6抑制剂致肝毒性的预测因素：真实世界队列研究
Hülya Ertaş,Burcu Caner,Arife Ulaş et al.
Hülya Ertaş et al.
BackgroundCDK4/6 inhibitors are standard treatments for HR+/HER2- metastatic breast cancer. While effective, hepatotoxicity is a significant clinical concern. This study aimed to evaluate the incidence and clinical predictors of hepatotoxic...
Osimertinib rechallenge using an oral anti-urticarial medication regimen following full body Urticaria: A case report [0.03%]
奥西替尼再挑战联合口服抗过敏药物治疗全身性荨麻疹1例
Mark Pulver,Mildred Kwan,Jared Weiss et al.
Mark Pulver et al.
IntroductionOsimertinib is a common treatment for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). EGFR inhibitors, such as osimertinib, are known to cause cutaneous toxicities including acneiform rash, pa...
Perceptions and needs of community pharmacy teams when caring for pediatric oncology patients : A multicenter study conducted in France [0.03%]
法国多中心研究中的社区药房团队在照顾儿童肿瘤患者时的感知和需求
C Moreau,C Fronteau,D Navas
C Moreau
IntroductionCommunity pharmacy staffs play an essential role in the care pathway for children with cancer. The diversity of pediatric cancers, the rarity of cases and the complexity of treatment protocols can pose challenges for community p...
Clinical outcomes in HTA appraisal reports of oncology medicines in Portugal: A cross-sectional analysis [0.03%]
葡萄牙HTA评估报告中关于肿瘤药物的临床结局：一项横断面分析
Pedro Teodoro,Catarina Ribeiro,Diogo Mendes et al.
Pedro Teodoro et al.
IntroductionReimbursement appraisals of medicines should emphasize outcomes clinically relevant to patients and clinicians. This study aims to characterize the outcomes selected in oncology reimbursement appraisal reports in Portugal.Method...
High-Dose methotrexate in pediatric acute lymphoblastic leukemia: Variability across Mexican centers from a national survey [0.03%]
墨西哥全国调查：墨西哥各地儿童急性淋巴细胞白血病高剂量甲氨蝶呤应用的差异性研究
Julia E Colunga-Pedraza,Oscar González-Ramella,Pablo González-Montalvo et al.
Julia E Colunga-Pedraza et al.
IntroductionHigh-dose methotrexate (HD-MTX) is a cornerstone of pediatric acute lymphoblastic leukemia (ALL) therapy. It's safe administration requires timely pharmacokinetic monitoring and comprehensive supportive care, which are frequentl...
Errors in the dilution/reconstitution of injectable preparations in oncology: Analysis of the most common errors, clinical consequences, and technological solutions to ensure safe hospital practice [0.03%]
肿瘤学中注射制剂的稀释/复溶错误：最常见的错误、临床后果及确保安全医院实践的技术解决方案分析
Boufaress Soukaina,Cherif Chefchaouni Ali,Hafidi Youssef et al.
Boufaress Soukaina et al.
ObjectiveThis review article was conducted to summarize the published literature on the most common errors and clinical consequences, and to explore technological solutions for securing the process of preparing chemotherapeutic drugs.Data s...
Practical considerations in the management of patients with atrial fibrillation/flutter and hematologic malignancies [0.03%]
血小板减少或其他血液系统恶性肿瘤患者的房颤/房扑的管理注意事项
Madeleine A Ochs,Nicholas Shabanowitz,Victoria R Nachar et al.
Madeleine A Ochs et al.
ObjectiveThe purpose of this review is to highlight the nuanced approach for managing drug-drug interactions (DDIs), anticoagulation challenges, and overlapping toxicities in patients with atrial fibrillation (AF) and hematologic malignanci...
A scoping review of renal function calculation methods for the dosing of carboplatin [0.03%]
卡铂给药的肾功能计算方法的综述性研究
Michal Sladkowski,Melanie Dalby,Hannan Mahamud
Michal Sladkowski
BackgroundCarboplatin is widely used to treat solid and haematological malignancies. The Calvert formula (area under the curve (AUC)×(glomerular filtration rate (GFR) + 25) is used globally to calculate the dose. Due to the large number of...
Real-world predictors of severe chemotherapy-induced neutropenia in non-Hodgkin lymphoma: Evaluation of biosimilar and reference rituximab [0.03%]
真实世界中非霍奇金淋巴瘤严重化疗引起的中性粒细胞减少症的预测因素：生物类似药与参照利妥昔单抗的评估
Dendhi Bagus Andriyanto,Nadia Farhanah Syafhan,Fitri Nurhayati
Dendhi Bagus Andriyanto
BackgroundThe adoption of rituximab biosimilars offers a cost-effective alternative for treating Non-Hodgkin Lymphoma (NHL). However, real-world safety data regarding severe hematological toxicities in the Indonesian clinical setting remain...
Preliminary development and content validation of mopet-A multidomain oncology pain assessment tool for cancer care setting [0.03%]
mopet-M多领域肿瘤疼痛评估工具的初步开发和内容有效性的验证
Manjula Gudhoor,Shrinivas Sonwalkar,Maheen Khazi et al.
Manjula Gudhoor et al.
PurposeCancer pain affects emotional, behavioural, social, and financial well-being beyond physical symptoms. Preliminary development and to perform content validation of a Multidomain Oncology Pain Assessment Tool incorporating physical, e...